Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Esmolol

Esmolol

Ultra short-acting **selective Ξ²1** blocker (IV)

AdultBBICUIV

Indication

AF RVR (acute) β€’ Peri-op tachycardia β€’ Aortic HR control (adjunct) β€’ Thyroid storm (ICU protocol adjunct)

At a glance

INDICATIONS (CORE USE)

**Acute** HR control β€” **AF/AFL RVR**, perioperative tachycardia, **aortic** protocols (after **vasodilator** per team β€” not monotherapy for dissection). **ICU / monitored** bed.

ADULT DOSE (STANDARD)

**IV infusion:** **load** optional per protocol β†’ **titrate** every few minutes to **HR/BP** endpoint **Offset minutes** after stop β€” plan reassessment

MAX DOSE

**Institutional infusion** max β€” **hypotension** limits dose before labeled mg cap

Route

IV only

PEDIATRIC DOSE

Rare PICU β€” specialist mg/kg protocols

Do not miss

Must-not-miss safety points

Major warning

- Hypotension / bradycardia during titration - Bronchospasm β€” not asthma-safe despite Ξ²1 selectivity - High potassium / AV conduction disease β€” synergy with other blockers

Indications

USE IF: need **minute-to-minute** HR control in **monitored** setting. AVOID IF: uncontrolled hypotension, high-grade AV block (without pacing), or severe asthma without airway plan.

Primary

  • Acute atrial fibrillation / flutter with **rapid ventricular response** β€” rate control
  • Perioperative **tachycardia** (anesthesia/cards protocol)
  • **Aortic dissection** β€” **HR control** as **adjunct** after **vasodilator therapy** (team protocol)

Secondary

  • Thyrotoxicosis / thyroid storm β€” **ICU adjunct** (after Ξ±-blockade in storm)

Dosing

STANDARD (ADULT PO)

**Load optional** β†’ **maintenance infusion** β€” pump + **continuous monitoring**

ADULT DOSE

Typical pattern: **500 mcg/kg load** over **1 min** (optional) β†’ **50 mcg/kg/min** start β†’ **↑ q 4 min** by **50–100 mcg/kg/min** to endpoint (max **~200–300 mcg/kg/min** institution-specific). **Hypotension** β†’ **↓ rate** or **stop** β€” effect clears quickly.

PEDIATRIC DOSE

PICU protocols only.

MAX DOSE

**Hypotension** usually limits before absolute mg cap

Practical Note

**Peripheral IV** extravasation β€” prefer **central** per policy; **compatibility** with line meds β€” pharmacy.

Warnings

Clinical warnings

  • Ultra short-acting IV beta1 β€” ICU / controlled setting only. DO NOT use without continuous HR/BP/ECG monitoring. HOLD for bradycardia, hypotension, high-grade AV block, or acute decompensated HF.
  • Combine with verapamil / diltiazem (especially IV) only with extreme caution β€” profound bradycardia / AV block / shock risk
  • Abrupt stop can rapidly remove beta-blockade and allow rebound tachycardia

Adverse effects

  • Hypotension
  • bradycardia
  • nausea
  • injection site issues

Contraindications

  • Severe sinus bradycardia
  • High-grade AV block (without pacing)
  • Cardiogenic shock
  • Decompensated HF needing inotrope (context)

Drug interactions

  • Verapamil / diltiazem (especially IV): avoid or use extreme caution (profound bradycardia / AV block / shock risk)
  • Digoxin: additive AV-node suppression / AV block risk
  • Amiodarone: additive AV-node suppression / bradycardia risk

Special populations

Pediatrics

Rare PICU β€” specialist mg/kg protocols

Pregnancy

**Pregnancy acute HTN:** **labetalol** often preferred β€” esmolol **case-by-case** OB/anesthesia. **

Lactation

** short exposure if brief use β€” context.

Renal impairment

Metabolized by **RBC esterases** β€” minimal renal adjustment.

Hepatic impairment

Minimal hepatic clearance β€” less dose change than oral BB in liver failure.

Elderly

Lower infusion rates often tolerated better β€” still titrate.

Administration

**Dedicated line** / compatible Y-site per pharmacy; **titration q few min**.

Monitoring

  • Monitor: - Symptoms β†’ dizziness, syncope, fatigue - **Continuous telemetry + BP** during titration
  • Recheck: - Reassess ECG / PR interval / AV block risk with symptoms, IV use, or dose escalation - Reassess dose / volume / cause within 48–72h after change - β€’ ICU infusion β†’ titrate frequently; offset within minutes of stopping β€” reassess q few min - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)
  • Hold if:
    - Hold if:
    - HR <50–55
    - SBP <90–100
    - Symptomatic bradycardia
    - Acute decompensated HF
    - Hypoperfusion / cardiogenic shock
    - Pulmonary edema requiring IV therapy

    Also hold:
    - High-grade AV block
    - Severe orthostasis

Overdose / toxicity

Clinical Picture

A) Mild β†’ bradycardia, hypotension, fatigue B) Moderate β†’ sustained bradycardia + hypotension Β± AV block C) Severe β†’ shock, high-grade AV block, seizures / coma (severe toxicity)

Immediate Actions

β€’ Airway + continuous monitoring first (ABCs, telemetry, BP) β€’ Bradycardia β†’ atropine β€’ Hypotension β†’ IV fluids β€’ Early β†’ IV calcium (CaCl2 / Ca-gluconate) β€’ Glucagon 3–5 mg IV β€’ Repeat or escalate glucagon β†’ infusion if responsive (often transient) β€’ Persistent shock β†’ HIET (insulin + dextrose) β€’ Monitor glucose + potassium closely β€’ Add vasopressors if shock persists β€’ Wide QRS / ventricular arrhythmia β†’ sodium bicarbonate (membrane-stabilizing toxicity) β€’ Refractory severe lipophilic toxicity β†’ IV lipid emulsion (toxicology-guided) β€’ Pacing β†’ symptomatic high-grade AV block β€’ ECMO β†’ refractory shock (per center) β€’ Severe / unstable β†’ ACLS + ICU / toxicology

Antidote

- Glucagon β†’ non-Ξ² pathway (often transient) - IV calcium β†’ inotropy / conduction support - HIET β†’ metabolic rescue (refractory shock) - IV lipid β†’ lipophilic toxicity (refractory / seizures)

Decontamination

β€’ Recent **oral** ingestion β†’ **activated charcoal** if **protected airway** and within **~1–2 h** (ingestion history + risk/benefit)

Escalation

- Wide QRS / ventricular arrhythmia β†’ sodium bicarbonate (membrane-stabilizing toxicity) - Pacing β†’ symptomatic high-grade AV block - ECMO β†’ refractory shock (per center)

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

**Turn off** infusion β†’ **effect gone fast** β€” use that for **trial** of tolerance.

Clinical pearls

**ICU drug** β€” ward initiation without monitoring unsafe. *Ξ²-blockers (class):* **Start low, go slow.** **HF:** only **evidence-based agents** (**metoprolol succinate**, **bisoprolol**, **carvedilol**) for **HFrEF GDMT** β€” not all Ξ²-blockers interchangeable. **Rate control (AF)** vs **BP lowering** β€” titrate to the clinical target.

Beta-blocker safety

  • Pump + telemetry
  • Hypotension = down-titrate first

Pharmacokinetics

TΒ½ ~**9 min** β€” steady state in **~30 min**; clears **within minutes** of stopping.

Mechanism of action

**Selective Ξ²1** antagonism; **ultra short** half-life (RBC esterase).

Common brand names

Saudi Arabia

Brevibloc, Esmolol

Global

(placeholder β€” verify local formulation)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Acute **aortic syndromes** and **thyrotoxic storm** are **protocol-driven** β€” Ξ²-blocker choice and targets are **team + guideline** specific.
  • Ξ²-blocker **GDMT for HFrEF** applies only to **evidence-based agents** β€” verify label and cardiology plan before substituting.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • ACC / AHA / HFSA heart failure and hypertension guidance
  • ESC cardiovascular and arrhythmia guidelines where applicable
  • FDA / SFDA product labeling
  • Institutional ICU / toxicology protocols (overdose)
  • ACC / AHA / HFSA heart failure and hypertension guidance
  • ESC cardiovascular and arrhythmia guidelines where applicable
  • FDA / SFDA product labeling
  • Institutional ICU / toxicology protocols (overdose)

Do not miss

  • Teach **not to stop abruptly** after chronic use β€” taper when feasible
  • Titrate to **HR vs BP endpoint** (AF rate control often needs higher exposure than BP alone)
  • Pump + telemetry
  • Hypotension = down-titrate first